Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72205-0063-01 72205-0063 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
72205-0062-01 72205-0062 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
72205-0061-01 72205-0061 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
71288-0158-96 71288-0158 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Oct. 23, 2020 In Use
71288-0132-90 71288-0132 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 28, 2021 In Use
71288-0119-20 71288-0119 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 2, 2021 In Use
72237-0104-01 72237-0104 selinexor XPOVIO 60.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
71332-0005-01 71332-0005 Olutasidenib REZLIDHIA 150.0 mg/1 Chemotherapy Enzyme Inhibitor IDH1 Oral Dec. 1, 2022 In Use
16571-0817-02 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0817-51 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0817-41 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-02 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-51 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-41 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-02 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-51 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-41 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-02 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-51 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-41 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-02 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-51 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-41 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
43598-0045-28 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0045-63 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use

Found 10,000 results in 8 millisecondsExport these results